The two deaths, which happened in Russia and Kazakhstan, occurred after a Zolgensma infusion and steroid doses intended to fight liver complications, according to Bloomberg.
Zolgensma is used for spinal muscular atrophy, a rare condition that’s present in 1 in every 10,000 people, according to the National Organization for Rare Disorders. Because this is the first report of deaths associated with the drug, Novartis will update the side effects label.
“While this is clinically important safety information, it is not a new safety signal and we firmly believe in the overall favorable risk/benefit profile of Zolgensma, which to date has been used to treat more than 2,300 patients worldwide across clinical trials, managed access programs, and in the commercial setting,” a Novartis spokesperson told Bloomberg.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
